CA3243297A1 - FITUSIRAN USED TO IMPROVE OUTCOMES REPORTED BY HEMOPHILIA PATIENTS - Google Patents

FITUSIRAN USED TO IMPROVE OUTCOMES REPORTED BY HEMOPHILIA PATIENTS

Info

Publication number
CA3243297A1
CA3243297A1 CA3243297A CA3243297A CA3243297A1 CA 3243297 A1 CA3243297 A1 CA 3243297A1 CA 3243297 A CA3243297 A CA 3243297A CA 3243297 A CA3243297 A CA 3243297A CA 3243297 A1 CA3243297 A1 CA 3243297A1
Authority
CA
Canada
Prior art keywords
fitusiran
qol
patient
hemophilia
questionnaire
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3243297A
Other languages
English (en)
French (fr)
Inventor
Shauna Andersson
Jose Bartelt-Hofer
Pronabesh DasMahapatra
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CA3243297A1 publication Critical patent/CA3243297A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3243297A 2021-12-22 2022-12-22 FITUSIRAN USED TO IMPROVE OUTCOMES REPORTED BY HEMOPHILIA PATIENTS Pending CA3243297A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202163293070P 2021-12-22 2021-12-22
US63/293,070 2021-12-22
US202263305550P 2022-02-01 2022-02-01
US63/305,550 2022-02-01
US202263335535P 2022-04-27 2022-04-27
US63/335,535 2022-04-27
US202263359717P 2022-07-08 2022-07-08
US63/359,717 2022-07-08
US202263382223P 2022-11-03 2022-11-03
US63/382,223 2022-11-03
US202263386489P 2022-12-07 2022-12-07
US63/386,489 2022-12-07
PCT/US2022/082213 WO2023122713A1 (en) 2021-12-22 2022-12-22 Fitusiran for use in improving patient-reported outcome in hemophilia patients

Publications (1)

Publication Number Publication Date
CA3243297A1 true CA3243297A1 (en) 2023-06-29

Family

ID=85227438

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3243297A Pending CA3243297A1 (en) 2021-12-22 2022-12-22 FITUSIRAN USED TO IMPROVE OUTCOMES REPORTED BY HEMOPHILIA PATIENTS

Country Status (10)

Country Link
US (1) US20250064842A1 (cg-RX-API-DMAC7.html)
EP (1) EP4452280A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500412A (cg-RX-API-DMAC7.html)
KR (1) KR20240138572A (cg-RX-API-DMAC7.html)
AU (1) AU2022419588A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243297A1 (cg-RX-API-DMAC7.html)
IL (1) IL313677A (cg-RX-API-DMAC7.html)
MX (1) MX2024007894A (cg-RX-API-DMAC7.html)
TW (1) TW202342065A (cg-RX-API-DMAC7.html)
WO (1) WO2023122713A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025171279A1 (en) * 2024-02-09 2025-08-14 Genzyme Corporation Treatment of hemophilia with fitusiran

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
JP2020530442A (ja) 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物
WO2022120291A1 (en) * 2020-12-06 2022-06-09 Genzyme Corporation Treatment of hemophilia with fitusiran

Also Published As

Publication number Publication date
MX2024007894A (es) 2024-08-20
JP2025500412A (ja) 2025-01-09
KR20240138572A (ko) 2024-09-20
AU2022419588A1 (en) 2024-08-01
WO2023122713A1 (en) 2023-06-29
US20250064842A1 (en) 2025-02-27
TW202342065A (zh) 2023-11-01
EP4452280A1 (en) 2024-10-30
IL313677A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
US20260014188A1 (en) Methods and compositions for treating hemophilia
Bussel et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life
Weinstein et al. Severe hyponatremia after repeated intravenous administration of desmopressin
US20240000744A1 (en) Treatment of Hemophilia with Fitusiran
TW202237151A (zh) 用非妥西蘭治療血友病
WO2022120291A1 (en) Treatment of hemophilia with fitusiran
Liebman et al. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII
US20250064842A1 (en) Fitusiran for Use in Improving Patient-Reported Outcome in Hemophilia Patients
TW202417014A (zh) 於小兒患者中以非妥西蘭治療血友病
WO2025059635A1 (en) Treatment of hemophilia a with fitusiran
US20240417739A1 (en) Compositions and methods for treatment of bleeding disorders
CN118434425A (zh) 用于改善血友病患者的患者报告结局的非妥西兰
WO2025171279A1 (en) Treatment of hemophilia with fitusiran
Gupta et al. Revolutionizing Treatment Strategies through Inhibition of Tissue Factor Pathway Inhibitor: A Promising Therapeutic Approach for Hemophilia Management.
Mannucci et al. Plasma‐derived and recombinant VWF concentrates
Pipe et al. 5 HEMOSTATIC

Legal Events

Date Code Title Description
A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240815

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240815

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240819

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240819

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250211

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251222

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251222